Pfizer (XSWX:PFE) Current Accrued Expense: CHF0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PFE Pfizer Inc XSWX:PFE
71 GF Score
Price CHF20.13
GF Value CHF21.20
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Current Accrued Expense?

Pfizer XSWX:PFE -1.35% 71 Current Accrued Expense is CHF0 Mil as of Mar. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 71/100 and a GF Value™ of CHF21.20 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Current Accrued Expense for the quarter that ended in Mar. 2026 was CHF0 Mil.

Pfizer Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Pfizer's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Current Accrued Expense Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:PFE
71GF Score
Pfizer Inc XSWX:PFE
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of CHF0 Mil mean?
Pfizer (XSWX:PFE) has a Current Accrued Expense of CHF0 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Pfizer and its competitors.
Is Pfizer's Current Accrued Expense too high?
Pfizer's current Current Accrued Expense is CHF0 Mil. Overall, Pfizer has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Current Accrued Expense compare to GILD and BMY?
Pfizer's Current Accrued Expense of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Pfizer and its competitors. Pfizer's current Current Accrued Expense is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.20, compared to a current price of CHF20.13 — trading 5% below its estimated fair value. The current Current Accrued Expense is CHF0 Mil. Pfizer's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Current Accrued Expense is CHF0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF20.13 is trading 5% below its estimated GF Value™ of CHF21.20. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Current Accrued Expense: CHF0 Mil
  • GF Value™: CHF21.20 vs. price of CHF20.13 (5% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
71GF Score

Get the complete analysis for XSWX:PFE

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.13
Price
CHF21.20
GF Value